Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00300196




Registration number
NCT00300196
Ethics application status
Date submitted
6/03/2006
Date registered
8/03/2006
Date last updated
12/01/2010

Titles & IDs
Public title
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Scientific title
ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke
Secondary ID [1] 0 0
NTI-ASP-0503
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Stroke 0 0
Cerebral Ischemia 0 0
Brain Infarction 0 0
Condition category
Condition code
Stroke 0 0 0 0
Haemorrhagic
Stroke 0 0 0 0
Ischaemic
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Ancrod (Viprinex)
Treatment: Drugs - Placebo

Experimental: Intravenous ancrod - Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.

Placebo comparator: Intravenous Placebo - Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.


Treatment: Other: Ancrod (Viprinex)
0.167 IU/kg/hr IV for 2-3 hours

Treatment: Drugs: Placebo
0.6 mL/kg/hr
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Modified Rankin Score - responder analysis
Timepoint [1] 0 0
90 days
Secondary outcome [1] 0 0
Barthel Index, NIHSS
Timepoint [1] 0 0
90 days

Eligibility
Key inclusion criteria
* Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment
* Baseline NIHSS > 5
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* No intracranial, extravascular blood on CT
* Hypertension (systolic > 185; diastolic > 105)
* Baseline fibrinogen level < 100 mg/dL
* Thrombocytopenia (< 100,000 / mm3)
* Recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent
* Recent (< 14 days) or anticipated surgery

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2008
Sample size
Target
Accrual to date
Final
311
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [2] 0 0
Gold Coast Hospital - Southport
Recruitment hospital [3] 0 0
Moash Medical Center Dept of Neurology - Clayton
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [5] 0 0
Alfred Hospital Research - Melbourne - Prahan, Melbourne
Recruitment hospital [6] 0 0
Concord Hospital Neuroscience Department - New South Wales
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
- Southport
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3050 - Parkville
Recruitment postcode(s) [5] 0 0
3184 - Prahan, Melbourne
Recruitment postcode(s) [6] 0 0
- New South Wales
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
West Virginia
Country [17] 0 0
Austria
State/province [17] 0 0
Graz
Country [18] 0 0
Austria
State/province [18] 0 0
Linz
Country [19] 0 0
Czech Republic
State/province [19] 0 0
Hradec-Kralove
Country [20] 0 0
Czech Republic
State/province [20] 0 0
Olomouc
Country [21] 0 0
Czech Republic
State/province [21] 0 0
Ostrava
Country [22] 0 0
Czech Republic
State/province [22] 0 0
Pardubice
Country [23] 0 0
Czech Republic
State/province [23] 0 0
Prague
Country [24] 0 0
Israel
State/province [24] 0 0
Ashkelon
Country [25] 0 0
Israel
State/province [25] 0 0
Beer Sheva
Country [26] 0 0
Israel
State/province [26] 0 0
Haifa
Country [27] 0 0
Israel
State/province [27] 0 0
Holon
Country [28] 0 0
Israel
State/province [28] 0 0
Jerusalem
Country [29] 0 0
Israel
State/province [29] 0 0
Nahariya
Country [30] 0 0
Israel
State/province [30] 0 0
Petach Tikva
Country [31] 0 0
Israel
State/province [31] 0 0
Tel Aviv
Country [32] 0 0
Israel
State/province [32] 0 0
Tel Hashomer
Country [33] 0 0
New Zealand
State/province [33] 0 0
Auckland
Country [34] 0 0
New Zealand
State/province [34] 0 0
Christchurch
Country [35] 0 0
Poland
State/province [35] 0 0
Gdansk
Country [36] 0 0
Poland
State/province [36] 0 0
Katowice
Country [37] 0 0
Poland
State/province [37] 0 0
Lublin
Country [38] 0 0
Poland
State/province [38] 0 0
Poznan
Country [39] 0 0
Poland
State/province [39] 0 0
Warsaw
Country [40] 0 0
Russian Federation
State/province [40] 0 0
Ekaterinburg
Country [41] 0 0
Russian Federation
State/province [41] 0 0
Jaroslavl
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Kazan
Country [43] 0 0
Russian Federation
State/province [43] 0 0
Moscow
Country [44] 0 0
Russian Federation
State/province [44] 0 0
Novosibirsk
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Petrozawodsk
Country [46] 0 0
Russian Federation
State/province [46] 0 0
Rostov-on Don
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Samara
Country [48] 0 0
Russian Federation
State/province [48] 0 0
St Petersburg
Country [49] 0 0
Russian Federation
State/province [49] 0 0
St. Petersburg
Country [50] 0 0
Slovakia
State/province [50] 0 0
Bratislava
Country [51] 0 0
Slovakia
State/province [51] 0 0
Levoca
Country [52] 0 0
Slovakia
State/province [52] 0 0
Martin
Country [53] 0 0
Slovakia
State/province [53] 0 0
Nitra
Country [54] 0 0
Slovakia
State/province [54] 0 0
Nova Ves
Country [55] 0 0
Slovakia
State/province [55] 0 0
Prestov
Country [56] 0 0
Slovakia
State/province [56] 0 0
Trnava
Country [57] 0 0
South Africa
State/province [57] 0 0
Worcester
Country [58] 0 0
Switzerland
State/province [58] 0 0
Lausanne
Country [59] 0 0
Switzerland
State/province [59] 0 0
Zurich

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Neurobiological Technologies
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Warren Wasiewski, M.D.
Address 0 0
Neurobiological Technologies
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00300196